Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001012338 | SCV001172772 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-09-11 | criteria provided, single submitter | clinical testing | The c.1594_1595delGTinsCA variant (also known as p.V532Q), located in coding exon 11 of the NBN gene, results from an in-frame deletion of GT and insertion of CA at nucleotide positions 1594 to 1595. This results in the substitution of the valine residue for a glutamine residue at codon 532, an amino acid with similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be neutral by in silico analysis (Choi Y et al. PLoS ONE. 2012; 7(10):e46688). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |